Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
In this week's podcast, we will dive into some of the most intriguing headlines from the biotech industry. Topics include the promise of radiolabeled antibody-drug conjugates (rADCs) for cancer treatment, the emerging potential of RNA editing as a new frontier in gene editing, and the rise of GPCR drugmaker Septerna. We'll also discuss the success of PureTech's innovative "hub-and-spoke" model for startups, and the recent resurgence of investment in biotech. Additionally, we'll cover the performance of key biotech companies like Intellia, Alto, Editas, Seaport, and Pfizer, along with insights on leadership and career development within the industry. Tune in for these stories and many more!
📣🎙️ TODAY’S POCAST:
[ 0:00 ] Intro
[ 1:25 ] rADCs for cancer treatment
[ 3:05 ] New obesity drugs
[ 4:13 ] RNAi emerges from CRISPR shadow
[ 6:09 ] New GPCR drugs - Septerna IPO
[ 7:00 ] Hub & spoke biotech model
[ 8:40 ] Cautious optimism for biotech
[ 9:49 ] NTLA in-vivo data disappoints
[ 11:23 ] Alto disappoints in depression
[ 13:14 ] Wall St support for Pfizer’s Bourla
[ 14:42 ] Positive biotech market momentum
[ 16:12 ] Remaining relevant between jobs
[ 20:22 ] Editas to focus on in-vivo editing
[ 25:25 ] Conclusion
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post